ClinicalTrials.gg
RecruitingNCT06628128Updated May 1, 2026

A Long-Term Study of JNT-517 in Participants With Phenylketonuria

A Phase 3 interventional study of JNT-517 in Phenylketonuria (PKU), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Recruiting at 12 sites in 2 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.

Planned enrollment
5th of 63
240 · median 33
Started
2025
with 5 others
Phase 3
16 of 93
3 open now
Primary completion
2027-11
later than 9 of 20 live
Registered
84th of 93
by date
Lead sponsor
5 of 93
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 93 studies in Phenylketonurias with a site in United States, this one is the 5th largest by planned enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2025, is one of 16 in phase 3, reaches primary completion later than 9 of the 20 other live ones, and was the 84th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Phenylketonurias with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase 3, open-label study is to evaluate the long-term safety of JNT-517 in pediatric and adult participants with Phenylketonuria (PKU) after completion of either Study JNT517-101 (NCT05781399) or JNT517-201 (NCT06637514) as well as participants who have not participated in a prior JNT-517 study. In this trial, all participants will receive JNT-517 using age- and weight-banded dosing as outlined in the protocol, regardless of any dose received in a previous study.

03

Conditions studied

  • Phenylketonuria (PKU)

Browse trials for

Keywords

  • Phenylketonuria
  • PKU
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of phenylketonuria (ie, PAH deficiency) by either molecular testing or biochemical criteria consistent with the applicable regional guidelines.
  2. Participants 4 years of age and older, inclusive, at time of Screening.
  3. Not on pegvaliase within 4 weeks of Screening.
  4. Not on sepiapterin within 2 weeks of Screening.
  5. If on sapropterin or large neutral amino acids at Screening, must be on a stable dose for 4 weeks prior to Screening.
  6. Willing and able to maintain a diet consistent in Phe content from the Screening period through the duration of the study, unless otherwise directed by a dietician as allowed in the protocol.
  7. Body weight ≥ 12.5 kg.
  8. If female of :

    1. Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test by Day 1.
    2. Must practice sexual abstinence, or if involved in any sexual intercourse that could lead to pregnancy, must agree to use 2 different methods, where at least 1 method must be highly effective, from Screening until at least 30 days after the last study drug administration.
    3. Must refrain from donating ova during the course of the study and for 30 days after the last dose of the study drug.
  9. Is a female not of childbearing potential or , defined as follows:

    1. Has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy).
    2. Has had amenorrhea for minimum of 1 year with confirmation by levels of follicle stimulating hormone testing.
    3. Has not achieved menarche (has not had first menstrual period). If a female achieves menarche during the study, she will need to follow the contraception requirement for females of childbearing potential.
  10. If male, must practice sexual abstinence, or if involved in any sexual intercourse that could lead to pregnancy, must agree to use 2 different contraceptive methods, where at least 1 method must be highly effective, from Day 1 until at least 30 days after the last study drug administration and must refrain from donating sperm during the course of the study and for 30 days after the last dose of the study drug.

    Note: No restrictions are required for males who have undergone a documented vasectomy at least 4 months prior to Screening. If the vasectomy procedure is not documented or was performed less than 4 months prior to Screening, males must follow the same contraception as for non-vasectomized participants.

  11. Capable of giving signed , or parent/legal guardian to provide informed consent and pediatric participant to give assent, and be able to comply with study procedures.
  12. Participants with psychiatric illness must be well-controlled for the last 3 months prior to screening visit and, if on medication, on stable medications for the last 3 months.

Key Exclusion Criteria:

  1. Participation in this study is not considered safe and/or feasible in the opinion of the Investigator.
  2. Participants have not completed a previous JNT-517 study and are eligible for another active JNT-517 trial at the site, unless approval is obtained from the medical monitor.
  3. Any acute or chronic medical condition that would prevent the participant from complying with the procedures or place the participant at risk if they participate in the study.
  4. Positive for or C or .
  5. Any history of significant liver disease.
  6. Any history of cataracts or more than minimal cataracts observed during the Screening ophthalmologic examination.
  7. Any surgical or medical conditions that may affect study drug absorption, distribution, metabolism, or excretion.
  8. Estimated \< 60 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2) by 2021 Chronic Kidney Disease Epidemiology Collaboration formula (participants aged 17 years or greater) or by Schwartz formula (participants aged 4 to 16 years of age).
  9. History of drug or alcohol abuse in the last year.
  10. Use of any medication that are inhibitors or inducers of cytochrome P450 (CYP)3A4 or inhibitors of the transporter P glycoprotein (P-gp) within 4 weeks prior to the first dose of study drug and unwilling and/or unable to avoid these medications throughout the treatment duration.
  11. Use of any medications that are a substrate of breast cancer resistance protein (BCRP), multidrug and toxin extrusion (MATE)1, MATE2-K, organic anion transporter 3 (OAT3), or within 4 weeks prior to the first dose of study drug and unwilling and/or unable to avoid these medications throughout the treatment duration (Appendix A). CYP3A4 substrates may be allowed if reduction in exposure is not expected to impact safety of the participant after consultation with the Medical Monitor.

    NOTE: Participants of childbearing potential will be permitted to continue with estrogen- or progesterone based oral contraceptives, but must agree to use 2 other methods of contraception, where at least 1 must be highly effective, or must agree to sexual abstinence during the study.

  12. Current, recent, or suspected infection within 2 weeks of Screening of Severe Acute Respiratory Syndrome Coronavirus 2/Coronavirus Disease 2019 (SARS-CoV-2/COVID-19).
  13. Unable to tolerate oral medication or inability to swallow tablets.
  14. Allergy to JNT-517 or any component of the product.
  15. Any of the following laboratory values at the Screening visit:

    1. or aspartate aminotransferase values ˃ 1.5 x the (ULN).
    2. Total ˃ULN unless history of Gilbert Syndrome and then total bilirubin >4 milligrams per deciliter [mg/dL] is exclusionary.
    3. ˂10.0 g/dL (˂100.0 grams per liter [g/L])
    4. White blood cell count ˃1 x ULN
    5. count ˂150 × 109/L (˂150,000/cubic millimeters[mm\^3])
  16. Participation in another investigational drug trial within 30 days (other than for JNT-517) or, if known 5 half-lives of investigational drug (whichever is longer).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    JNT-517

    Drug: JNT-517

Interventions

  • JNT-517 administered orally twice daily using age- and weight-banded dosing.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Reported based on results of 12-lead electrocardiograms (ECGs), vital signs, clinical laboratory tests, and other medical assessments.

    Time frame: Screening to +2 weeks from last dose

Secondary outcomes

  1. Absolute Change from Baseline in Plasma Phe

    Time frame: Baseline to +2 weeks from last dose

  2. Percent Change from Baseline Over Time in Plasma Phe

    Time frame: Baseline to +2 weeks from last dose

  3. Percentage of Participants with Plasma Phe <600 micromoles (µM) Over Time in Participants with Baseline Phe >600 µM

    Time frame: Baseline to +2 weeks from last dose

  4. Percentage of Participants with Plasma Phe ≤360 µM Over Time in Participants with Baseline Phe >360 µM

    Time frame: Baseline to +2 weeks from last dose

  5. Percentage of Participants with Plasma Phe ≥120 µM Over Time in Participants with Baseline Phe >120 µM

    Time frame: Baseline to +2 weeks from last dose

  6. Change from Baseline Over Time in Urinary Phe and Other Amino Acids

    Time frame: Baseline to +2 weeks from last dose

  7. Absolute Change from Baseline Over Time in Dietary Phe Intake

    Absolute change from baseline over time in dietary Phe intake (milligrams per kilogram per day \[mg/kg/day\]) for participants achieving plasma Phe ≤360 μM

    Time frame: Baseline to +2 weeks from last dose

  8. Absolute Change from Baseline Over Time in Dietary Intact Protein Intake (grams per kilogram per day [g/kg/day]) for Participants Achieving Plasma Phe ≤360 μM

    Time frame: Baseline to +2 weeks from last dose

  9. Percentage of Participants who Increase Phe Intake Over Time While Maintaining Plasma Phe ≤360 μM

    Time frame: Baseline to +2 weeks from last dose

  10. Absolute Change from Baseline Over Time in the Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) in Pediatric Participants who Previously Participated in JNT517-301

    Time frame: Month 6, Month 12, and yearly thereafter up to approximately 5 years

  11. Plasma Concentrations Over Time in de novo Participants Aged 4 to 11 Years

    Time frame: Day 1 (1-hour postdose), and predose and 1-hour postdose on Day 7 and Day 14

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Nov 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2024
First posted
Oct 4, 2024
StartActual
Aug 11, 2025
Primary completionEst.
Nov 1, 2027
CompletionEst.
Feb 1, 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06628128
Responsible party
Sponsor
First posted
Oct 4, 2024
Start date
Aug 11, 2025
Primary completion
Nov 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Otsuka Call Center
Contact
otsuka-professionalservices@otsuka-us.com
844-687-8522

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repinatrabit

Start the discussion